Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.
Actively Recruiting
This research aims to gather detailed data and biomaterials from adults diagnosed with Acute Lymphoblastic Leukemia ALL and related diseases, including certain types of Leukemia and Non-Hodgkins Lymphoma. The registry supports ALL research and quality assurance by collecting information regardless of whether patients participate in clinical trials. The study is observational and involves adults diagnosed and treated under ALL protocols. Participants include adults aged 18 and older with ALL subtypes, other leukemias treated according to ALL protocols, and specific subtypes of Non-Hodgkins Lymphoma treated under B-ALL protocols. The study collects data prospectively on diagnosis, treatment, and outcomes, along with biomaterials related to these conditions. Participants provide information during routine clinical care and follow-up visits for up to 10 years. Data collected includes survival rates, remission status assessed by various methods including PET scans, relapse rates, quality of life questionnaires, and monitoring of toxicities and comorbidities. The study tracks overall survival and other outcomes over long-term follow-up to support research and quality assurance in adult ALL and related diseases.
Actively Recruiting
Researchers are evaluating the safety and functional outcomes of intravenous thrombolysis IVT in adult patients who have recently taken direct oral anticoagulants DOACs and experienced an acute ischemic stroke. This international, prospective observational registry aims to understand whether IVT can be safely administered to these patients and if it improves recovery. The study involves collecting data from about 2800 participants across multiple stroke centers and comparing three groups based on recent DOAC intake and IVT treatment status. Participants are divided into three groups those who have taken DOACs recently and receive IVT, those who have taken DOACs recently but do not receive IVT, and patients without recent DOAC intake who receive IVT. The study collects detailed information about the timing, dose, and type of IVT drugs used Tenecteplase and Alteplase, as well as any complications that occur. The follow-up period lasts 90 days after the stroke event. During the study, researchers will monitor participants for symptomatic intracerebral hemorrhage within 36 hours after IVT and assess functional outcomes at 90 days using the modified Rankin Scale. Secondary evaluations include stroke severity, stroke volume, mortality, major bleeding, and other adverse events within specified timeframes. Data collection involves clinical assessments and imaging to understand stroke progression and treatment effects. Participants are observed for an average of two years for related study outcomes.
Actively Recruiting
Researchers are conducting a registry study involving adult patients diagnosed with acute myeloid leukemia AML and related myeloid neoplasms, including newly diagnosed or relapsedrefractory cases. The study aims to collect comprehensive data on patient characteristics, family history, biological disease profiles, and clinical outcomes. It also focuses on analyzing disease-related genetic markers and the impact of measurable residual disease MRD using various methods. The study does not involve specific treatments but collects data and biological samples such as bone marrow, blood, plasma, and normal tissue including skin biopsies and other specimens. This observational study enrolls patients from around 80 to 90 sites in Germany and Austria. Patients treatment responses, decisions, and outcomes are tracked over time. Participants are observed for up to 10 years, during which researchers gather information on treatment response, survival, relapse rates, quality of life, and genetic markers. The study includes assessments of event-free survival, relapse-free survival, cumulative incidence of relapse and death, and overall survival. Patient consent is required for registration, data storage, and biobanking of specimens for analysis throughout the observation period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intravenous thrombolysis IVT in adults who have had an acute ischemic stroke AIS and recently taken direct oral anticoagulants DOACs within the last 48 hours. This international, multicenter, randomized study aims to determine whether IVT combined with standard medical care leads to better outcomes at 90 days compared to standard care alone. The trial is designed as a phase 4 superiority study enrolling 906 participants at several high-volume stroke centers worldwide. Participants will be randomly assigned to one of two groups one group will receive intravenous thrombolysis using Tenecteplase or Alteplase along with the best standard medical treatment, while the other group will receive only the standard of care as per local and international guidelines. Treatment must begin within specific time windows based on stroke onset or MRI findings. The study follows current guidelines from major stroke organizations, ensuring participants receive appropriate care. During the study, participants will be monitored and assessed using the Modified Rankin Scale at 90 days to evaluate functional outcomes. Additional measures include stroke severity changes assessed by the NIH Stroke Scale within 24 hours, and quality of life questionnaires at 90 days. The study includes careful safety monitoring and long-term follow-up to fully assess treatment effects and participant well-being throughout and after the 90-day period.